AS Latvijas Juras medicinas centrs (UOM) - Net Assets
Based on the latest financial reports, AS Latvijas Juras medicinas centrs (UOM) has net assets worth €6.33 Million EUR (≈ $7.40 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€8.73 Million ≈ $10.20 Million USD) and total liabilities (€2.40 Million ≈ $2.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read UOM liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.33 Million |
| % of Total Assets | 72.48% |
| Annual Growth Rate | -1.17% |
| 5-Year Change | -0.23% |
| 10-Year Change | -9.3% |
| Growth Volatility | 7.9 |
AS Latvijas Juras medicinas centrs - Net Assets Trend (2015–2025)
This chart illustrates how AS Latvijas Juras medicinas centrs's net assets have evolved over time, based on quarterly financial data. Also explore AS Latvijas Juras medicinas centrs total assets for the complete picture of this company's asset base.
Annual Net Assets for AS Latvijas Juras medicinas centrs (2015–2025)
The table below shows the annual net assets of AS Latvijas Juras medicinas centrs from 2015 to 2025. For live valuation and market cap data, see market cap of AS Latvijas Juras medicinas centrs.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €6.33 Million ≈ $7.40 Million |
+2.61% |
| 2024-12-31 | €6.17 Million ≈ $7.21 Million |
-0.62% |
| 2023-12-31 | €6.20 Million ≈ $7.25 Million |
-8.85% |
| 2022-12-31 | €6.81 Million ≈ $7.96 Million |
+7.35% |
| 2021-12-31 | €6.34 Million ≈ $7.41 Million |
+14.94% |
| 2020-12-31 | €5.52 Million ≈ $6.45 Million |
+0.26% |
| 2019-12-31 | €5.50 Million ≈ $6.43 Million |
-0.55% |
| 2018-12-31 | €5.53 Million ≈ $6.47 Million |
-7.13% |
| 2017-12-31 | €5.96 Million ≈ $6.96 Million |
-14.59% |
| 2016-12-31 | €6.97 Million ≈ $8.15 Million |
-2.03% |
| 2015-12-31 | €7.12 Million ≈ $8.32 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AS Latvijas Juras medicinas centrs's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.57 Million | 40.59% |
| Other Components | €3.76 Million | 59.41% |
| Total Equity | €6.33 Million | 100.00% |
AS Latvijas Juras medicinas centrs Competitors by Market Cap
The table below lists competitors of AS Latvijas Juras medicinas centrs ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
APB Resources Bhd
KLSE:5568
|
$5.92 Million |
|
Rebosis
JSE:REB
|
$5.93 Million |
|
B90 HOLDINGS PLC
F:24GN
|
$5.93 Million |
|
Moving iMage Technologies Inc
NYSE MKT:MITQ
|
$5.93 Million |
|
HIGH QUALITY FOOD
F:L24
|
$5.90 Million |
|
Viji Finance Limited
NSE:VIJIFIN
|
$5.90 Million |
|
THG Holdings PLC
LSE:THG
|
$5.90 Million |
|
CU Medical Systems Inc
KQ:115480
|
$5.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AS Latvijas Juras medicinas centrs's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,165,102 to 6,326,098, a change of 160,996 (2.6%).
- Net income of 240,996 contributed positively to equity growth.
- Dividend payments of 80,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €241.00K | +3.81% |
| Dividends Paid | €80.00K | -1.26% |
| Total Change | €- | 2.61% |
Book Value vs Market Value Analysis
This analysis compares AS Latvijas Juras medicinas centrs's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.94x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €7.29 | €7.40 | x |
| 2018-12-31 | €6.92 | €7.40 | x |
| 2019-12-31 | €6.88 | €7.40 | x |
| 2020-12-31 | €6.90 | €7.40 | x |
| 2021-12-31 | €7.93 | €7.40 | x |
| 2022-12-31 | €8.51 | €7.40 | x |
| 2023-12-31 | €7.75 | €7.40 | x |
| 2024-12-31 | €7.71 | €7.40 | x |
| 2025-12-31 | €7.91 | €7.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AS Latvijas Juras medicinas centrs utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.34%
- • Asset Turnover: 1.18x
- • Equity Multiplier: 1.38x
- Recent ROE (3.81%) is above the historical average (2.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -6.03% | -6.48% | 0.66x | 1.42x | €-998.00K |
| 2016 | -1.58% | -1.63% | 0.70x | 1.40x | €-718.81K |
| 2017 | 3.84% | 3.54% | 0.85x | 1.27x | €-359.40K |
| 2018 | 0.63% | 0.52% | 0.94x | 1.29x | €-518.62K |
| 2019 | 2.98% | 2.26% | 1.03x | 1.29x | €-386.05K |
| 2020 | 4.96% | 3.86% | 0.96x | 1.33x | €-278.07K |
| 2021 | 13.88% | 9.40% | 1.13x | 1.30x | €246.21K |
| 2022 | 9.19% | 6.45% | 1.10x | 1.30x | €-54.90K |
| 2023 | -10.06% | -6.34% | 1.09x | 1.46x | €-1.24 Million |
| 2024 | 3.00% | 1.82% | 1.13x | 1.47x | €-431.35K |
| 2025 | 3.81% | 2.34% | 1.18x | 1.38x | €-391.61K |
Industry Comparison
This section compares AS Latvijas Juras medicinas centrs's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $5,863,591,555
- Average return on equity (ROE) among peers: -73.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AS Latvijas Juras medicinas centrs (UOM) | €6.33 Million | -6.03% | 0.38x | $5.92 Million |
| China Resources Medical Holdings Company Limited (1PH) | $7.01 Billion | 3.67% | 0.95x | $428.88 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $-125.88 Million | 0.00% | 0.00x | $3.30 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $10.35 Billion | 2.73% | 0.45x | $720.78 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.34 Billion | 4.88% | 1.24x | $19.18 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $24.10 Billion | 29.08% | 0.21x | $50.59K |
| Eifelhöhen-Klinik AG (EIF) | $9.88 Million | -19.11% | 6.64x | $8.99 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $2.01 Billion | -12.28% | 1.84x | $12.02 Billion |
| Fresenius Medical Care AG & Co. KGaA (FMEA) | $10.83 Billion | 11.82% | 1.22x | $11.58 Billion |
| Fresenius SE & Co. KGaA (FRE) | $3.10 Billion | 10.64% | 3.84x | $27.16 Billion |
About AS Latvijas Juras medicinas centrs
AS Latvijas Juras medicinas centrs provides health care services in the Republic of Latvia. The company engages in the general and special medical practice, dental practice, human health, residential nursing care, residential care, social work, physical well-being, and other personal service activities. It also involved in provision of other education services related activities. In addition, the… Read more